Company ProfilePremium

PMC Group Inc.

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
PMC Group Inc. - Company showcase

Year Founded & Workforce

1994

PMC Group Inc. logo

PMC Group Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

PMC Group Inc. Overview

PMC Group is a founder-owned, acquisition-built US specialty chemicals and pharmaceutical-manufacturing conglomerate headquartered in Mount Laurel, New Jersey. Since 1994 it has assembled more than twenty carve-outs from global chemical majors – including PPG, BASF, ExxonMobil, ICI, Nova Chemicals, Chemtura, Arkema, Dow, AkzoNobel and Lanxess – typically acquiring non-core, mature niche product lines and repositioning them under PMC brands. Today the group describes itself as a global manufacturer of intermediate chemicals for industrial and specialty markets [S1], organized into nine business units: organotin stabilizers and catalysts (PMC Organometallix), renewable-based oleochemical derivatives (PMC Biogenix), defoamers and wax emulsions (PMC Crystal), flame-retardant and additive masterbatches (PMC Polymer Products), specialty esters (PMC Ouvrie), rubber chemicals in India, pharmaceutical CDMO services in France (PMC Isochem) and India, and nitroglycerin/energetic materials (Copperhead Chemical). Its competitive model rests on niche leadership, owner-operator decision speed and opportunistic portfolio rotation rather than scale.


Company's own description

On its current website, PMC Group characterizes itself as a global manufacturer of intermediate chemicals serving a broad range of industrial and specialty markets, emphasizing technical expertise, operational reliability, consistent quality and dependable supply; its tagline is "Technical Expertise. Reliable Supply. Proven Performance." [S1]. Earlier press-release boilerplate (2019–2021) described PMC as a US-based, growth-oriented, diversified global chemicals and pharmaceuticals company serving plastics, consumer products, electronics, coatings, packaging, mining, personal care, food, automotive and pharmaceuticals, built on growth through innovation while promoting social good [S3][S8]. The April 2026 boilerplate adds that PMC sources over half of its raw materials from renewable feedstocks [S19].

The shift in self-description – from "growth-oriented diversified chemicals and pharmaceuticals company" (2019–2021) to "global manufacturer of intermediate chemicals" with a reliability-of-supply message (2025–2026) – is analytically meaningful: it coincides with retrenchment (Memphis closure, exit from commodity fatty acids) and a website redesign, and suggests management is emphasizing supply security and operational dependability over expansionary diversification.

Independent characterization

PMC Group is best understood as a private, family-controlled roll-up of corporate carve-outs in mature, niche chemistries. The business model has three recurring features:

  1. Carve-out acquisition from majors. Of the 24 dated milestones on the company's history page, 20 are acquisitions, and almost all are divisions divested by large multinationals (BASF ×3, Arkema ×2, PPG, ExxonMobil, ICI, Nova, Chemtura, Dow, AkzoNobel, Lanxess, Ecolab, Nexen, Isochem/Aurelius) [S2]. Purchase prices have consistently been undisclosed.

  2. Niche concentration. Several units occupy small, consolidated global markets: organotin PVC heat stabilizers and tin catalysts (where the 2012–2013 Arkema and Dow deals gave PMC "a large share" of the world tin PVC stabilizer market, per the International Tin Association [S11]); fatty primary amides (Armoslip®, Kemamide®); and pharmaceutical-grade nitroglycerin, where Copperhead has been described as the sole US manufacturer of FDA-approved nitroglycerin for over 70 years [S8][S9].

  3. Asset rationalization after acquisition. PMC routinely restructures acquired footprints – e.g., relocating Lanxess organotin production from Bergkamen, Germany to Axis, Alabama and Carrollton, Kentucky (2020–2022) [S10], and closing the legacy Memphis oleochemicals plant (April 2026) after shifting amide capacity to South Korea [S12][S16].

Revenue model

Revenue typeShare of revenueDescription
Product sales (specialty/intermediate chemicals)Not publicly disclosed (assessed as the large majority)Organotin stabilizers/catalysts, fatty amides/esters, metallic stearates, defoamers, wax emulsions, masterbatches, specialty esters, rubber chemicals
Pharmaceutical products (APIs, intermediates, excipients, bulk drug substance)—PMC Isochem (France), PMC YM-Pharma / PMC Pharmaceuticals India, Copperhead (nitroglycerin bulk drug substance listed with FDA as bulk ingredient [S26][S27])
Contract/custom manufacturing services (CDMO)—Custom synthesis, process development, scale-up at PMC Isochem; custom dosage-form manufacturing at Copperhead [S6][S9]
Defense energetic materials—Copperhead supplies energetic chemicals (explosives and propellants) to the defense sector [S8][S31]
Licensing / subscriptionNone disclosed—

Value-chain position

PMC sits in the mid-stream intermediate and additive layer: it buys tin metal, fatty acids/oils, glycerin, petroleum waxes and basic chemicals, and sells performance additives and intermediates to compounders, formulators, converters and drug manufacturers. Its products are typically low-percentage-by-weight but performance-critical inputs (heat stabilizers in rigid PVC, slip agents in polyolefin film, catalysts in coatings and urethanes, defoamers in food processing). This position confers pricing power when supply is concentrated (evidenced by the 10–25% across-the-board price increase announced by PMC Organometallix in April 2026 [S19]) but exposure to raw-material swings (tin, fatty-acid feedstocks) and to substitution and regulatory risk.

Customer types and end-markets

End-marketPrimary PMC units serving itExample products
Plastics / PVC (building & construction, packaging)Organometallix, Biogenix, Polymer ProductsOrganotin heat stabilizers; Armoslip®/Kemamide® slip and anti-block amides; flame-retardant masterbatches
Coatings, inks, adhesivesOrganometallix, CrystalFASCAT® tin catalysts; CrystalCer® wax emulsions [S20][S25]
Food processing & fermentationCrystal, OuvrieFood/fermentation defoamers (ex-BASF business) [S2]
Rubber / tiresPMC Rubber Chemicals (India), CrystalAccelerators, antioxidants, antiozonants, antiozonant waxes [S21]
Electronics & wire/cableCrystal, Polymer ProductsCable-filling compounds, antistatic masterbatches [S5][S21]
Personal care & consumer productsBiogenix, OuvrieGlycerol esters, specialty esters [S12]
PharmaceuticalsIsochem, YM-Pharma/PMC Pharmaceuticals India, CopperheadAPIs, intermediates, excipients, NCA/polyamino acids, bulk nitroglycerin [S6][S7][S9]
DefenseCopperheadEnergetic materials for propellants and munitions (business-level description only) [S8][S31]
Mining, automotiveGroup-wideCited in boilerplate [S3][S19]

Strategy

Stated strategic themes

PMC publishes no annual report or investor day. Recurring strategic themes from press releases and the website are:

  1. Growth through acquisition of niche specialty businesses, with the 2008 statement that the group's growth strategy centered on specialty chemicals and engineered resins [S5].

  2. Commitment to the organotin industry and to being customers' preferred organotin supplier, backed by capacity investment [S4][S10].

  3. Building an end-to-end pharma CDMO spanning all phases of drug development and manufacturing across three continents (US, Europe, India) [S8].

  4. Higher-value focus in oleochemicals, exiting commodity fatty acids [S12].

  5. Reliability of supply and technical expertise as the 2025–2026 brand promise [S1].

  6. Sustainability via renewable feedstocks – over half of raw materials from renewable sources [S19] – and "growth through innovation while promoting social good" [S3].

Strategic initiatives – last 24 months (Oct 2024 – Oct 2026)

InitiativeDateTypeDetailSource
Gyeongju Armoslip® expansionConstruction from late 2024; supply by mid-2026Capacity investment+50% production capacity for fatty amides[S12]
Memphis restructuring and closureProduct review 2024; WARN Feb 2026; closure 26 Apr 2026Restructuring / footprint consolidationExit commodity bulk fatty acids; then full closure, 172 jobs[S12][S16]
Organometallix global price increaseAnnounced 24 Apr 2026; effective 1 May 2026Commercial / pricing+10–25% on all product lines globally[S19]
Corporate rebrand and website relaunch2025–2026BrandNew BU logos; "Chemistry that powers performance" messaging[S1]

Earlier strategic programs still shaping the portfolio

InitiativeDateDetailSource
Organotin US capacity expansion2020–early 2022Axis, AL (intermediates) and Carrollton, KY (catalysts), relocating Bergkamen production[S10]
Pharma platform build2017–2021YM-Pharma, Isochem, Copperhead[S6][S7][S8]
Africa distributionJun 2021Safic-Alcan exclusive/authorized distribution for FASCAT®[S15]

Medium-term financial targets / guidance

Not publicly disclosed. PMC issues no financial guidance.

Products & Services

Pricing models are not publicly disclosed for any product line; PMC sells on contract and spot terms, and has used across-the-board percentage price increases (Biogenix Nov 2020 [S13]; Organometallix +10–25% from May 2026 [S19]).

PMC Organometallix (organotin chemistry)

Product lineDescription / capabilitiesTarget customersOrigin / latest disclosed dateFlagship
Organotin PVC heat stabilizers (methyl tin and other organotins)Thermal stabilization of rigid PVC during processing (pipe, profile, sheet, packaging)PVC compounders and convertersArkema (2012), Dow methyl tin (2013) [S11]Brand names not confirmed in sources reviewed
Heavy-metal-free organic polymer stabilizersNon-tin, non-heavy-metal stabilizer systemsPVC processors seeking regulatory-compliant alternativesDow (2013) [S11]—
Polymer lubricants / solid lubricants & multi-component one-pack systemsProcessing lubricants combined with stabilizersPVC processorsDow (2013) [S11]—
FASCAT® organotin catalystsSelective catalysts for esterification, transesterification, urethane and siloxane condensation; lower reaction temperatures and faster rates; used in coatings and e-coat curingCoatings, polyester resin, urethane, silicone producersArkema (2012); expanded by Lanxess line (2019); Carrollton capacity expansion 2020–2022 [S10][S25]FASCAT® 4102 (butyltin tris-2-ethylhexanoate, hydrolytically stable) [S20]
Organotin specialties & intermediates (ex-Lanxess)Global organotin catalyst, specialty and intermediate linesDownstream organotin and catalyst usersLanxess, closed Dec 2019 [S3]—
Tin intermediates / fine chemicals & reagentsOrganotin intermediates (expanded at Axis, AL) and reagentsChemical and fine-chemical manufacturers2020–2022 expansion [S10]—
Organophosphine-based productsOrganophosphine stabilizers/fine chemicalsSpecialty usersArkema (2012) [S11]—

Note: ChemPoint lists 84 PMC Organometallix products in its plastics catalogue and describes the Carrollton, KY site as a 400-acre facility [S25].

PMC Biogenix (renewable oleochemical derivatives)

Product lineDescriptionTarget customersStatusFlagship
Fatty amides and bisamidesSlip, anti-block, release and lubricant additives for polyolefin films and plasticsFilm and packaging converters, compoundersCore focus post-2024; Gyeongju capacity +50% targeted mid-2026 [S12]Armoslip® (ex-AkzoNobel, 2013), Kemamide® (ex-Chemtura, 2008)
Glycerol estersAntistatic/anti-fog and emulsifier applicationsPlastics, food, personal careRetained core [S12]Kemester®
Specialty estersLubricants, emollients, processing aidsPersonal care, industrialRetained core [S12]Kemester®
Metallic stearatesAcid scavengers, lubricants, release agentsPlastics, rubberRetained core [S12]Lubrazinc®
Merchant commodity bulk fatty acidsBulk fatty acids sold to third partiesIndustrialExited (announced June 2024) [S12]—
Glycerin, process acidsBy-products/derivatives of oleochemical processingIndustrialHistorically listed [S21]—

PMC Crystal (Lansdale, PA)

Product lineDescriptionTarget customersOriginFlagship
Specialty antifoams & defoamersFoam control for industrial and food/fermentation processesFood processors, fermentation, paper, coatingsCrystal Soap (1995); BASF food & fermentation defoamers (2012) [S2][S5]—
Wax emulsionsWater resistance, dust control, slip and lubricityInks, coatings, corrugated box coatingsExxonMobil wax emulsions (2005) [S2][S20]CrystalCer® C (acid-sensitive paraffin emulsion); CrystalCer® 90 (anionic, acid-stable) [S20]
Metallic stearatesLubricants/release agentsRubber, plasticsCrystal [S5]—
Rubber & plastic processing aidsProcessing aidsRubber/plastics compoundersCrystal [S5]—
Cable filling compoundsWater-blocking gels for cablesWire & cable makersCrystal [S5]—
Specialty petrolatum & waxesSpecialty wax productsIndustrial, rubber (antiozonant waxes)Crystal [S5][S21]—

PMC Polymer Products (Stockertown, PA)

Product lineDescriptionTarget customersOrigin
Flame-retardant masterbatches & compoundsDesign and development of flame-retardant additive concentratesPlastics compounders, electronics, building productsPPG Polymer Products (1994) [S2][S5]
Additive masterbatches (incl. antistatic)Custom additive concentratesFilm and molded-part producers[S5][S21]
Ignition-resistant polyolefins & styrenicsIgnition-resistant polystyrene (Avantra®, ex-BASF 2000; Zyntar®, ex-Nova 2006)Electronics housings, appliances[S2][S21] (current commercial status of Avantra®/Zyntar® brands not confirmed)

PMC Ouvrie (Lesquin, France)

Product lineDescriptionTarget customersOrigin
Specialty estersEsters for multiple applicationsIndustrial, personal care, foodBASF Ouvrie (1999); Delchim/Sacap (2003) [S2][S5]
DefoamersProcess foam controlFood and general industry[S5][S9]
Surfactants & protective colloidsFormulation aidsFood and general industrial[S9]

PMC Rubber Chemicals (India)

Product lineDescriptionTarget customersOrigin
AcceleratorsVulcanization acceleratorsTire and rubber goods makersICI India rubber chemicals (2005) [S2][S21]
Antioxidants & antiozonantsRubber protection chemicalsTire and rubber goods makers[S21]

PMC Isochem (France)

OfferingDescriptionTarget customersNotes
Custom synthesis / CDMOResearch, process development, regulatory support, pilot and full-scale production of intermediates and APIsMajor pharma companies (oncology, cardiovascular, infectious, GI, neurology, rare diseases)Acquired Dec 2017 [S6][S30]
Excipients & APIsManufacture of excipients and active ingredientsPharma, cosmetics~50 years' experience; ~250 staff across 3 sites (2025) [S23]
Specialty chemistriesPhosgene chemistry (Vert-le-Petit); fractional distillation (Gennevilliers); pressure hydrogenation and waste processing (Pithiviers)Pharma/fine chemicals[S22]
ISODEL® drug deliveryNCA (N-carboxyanhydride) and polyamino acid (PAA) "one-stop shop" for drug deliveryDrug-delivery developersTrade-press headlines; undated in sources [S35]
Protein engineering, drug development & discovery servicesService offerings cited by PMC in 2021Biotech/pharma[S8]

PMC Pharmaceuticals India / PMC YM-Pharma (Hyderabad)

OfferingDescriptionTarget customersNotes
Fluoroquinolone APIscGMP plant described as one of India's largest fluoroquinolone manufacturers; zero-discharge effluent systemGeneric drug makersAcquired 2017 [S7]
Generic APIs & intermediates (expansion focus)Oncology, neuropsychiatry, GI, pulmonary hypertension, anti-depressant, anti-migraineGlobal generics marketStated 2017 ambition [S7]
Process developmentAdvanced pharmaceutical intermediate manufacturingPharma[S8]

Copperhead Chemical (Tamaqua, PA)

OfferingDescriptionTarget customersNotes
Pharmaceutical-grade nitroglycerin (diluted, bulk ingredient)FDA-listed bulk drug substance supplied for further manufacturing; multiple NDC package codes active in 2026Cardiovascular drug manufacturers, compoundersDescribed as sole US maker of FDA-approved nitroglycerin for 70+ years [S8][S26][S27]
Other DMF-listed bulk substancesPharmaCompass lists DMF entries including SDM-78 (US DMF and Japanese DMF)Pharma[S27]
Custom dosage-form manufacturingCustom manufacturing of drug dosage formsPharma[S9]
Energetic materials for defenseNitrate-ester-based energetic chemicals for propellants and munitions (business-level description only)US defense primes (e.g., Northrop Grumman award, 2022)[S8][S31][S33]
Preservatives & antimicrobialsA "novel class" of preservatives and antimicrobialsPharma/industrial[S8]
Technical & analytical servicesMaterial analyses, test-method development, instrument calibrationDefense/pharma[S31]

Financial Narrative

Disclosure status: PMC Group, Inc. does not publish consolidated financial statements. No revenue, profit, balance-sheet, cash-flow or ratio data for the group has been publicly disclosed in any source reviewed. Third-party "estimated revenue" figures returned by web searches for "PMC Group" relate to unrelated companies (see disambiguation) and are excluded. All values below are therefore NA (not publicly disclosed).

Income statement

Revenue CAGR FY2021–FY2025: not publicly disclosed.

Commentary on trends, inflections and drivers (qualitative, evidence-based)

Even without disclosed financials, the public record allows several directional inferences about PMC's financial trajectory over FY2021–FY2026:

Revenue drivers. FY2021–FY2022 likely benefited from the global post-pandemic specialty-chemicals pricing cycle and from the full-year consolidation of Copperhead (acquired February 2021) and the ex-Lanxess organotin line (closed December 2019) as Bergkamen volumes were relocated to US sites during 2020–early 2022 [S8][S10]. Peer evidence from listed tin-chemicals competitor Songwon indicates that 2025 was a soft year for the industry: Songwon's consolidated sales fell 2.9% to KRW 1,039,162M, with its tin intermediates business citing weak demand, intensified competition, declining prices and European logistics issues during 2025 [S28]. PMC's organotin business, exposed to the same PVC and coatings demand, is likely to have faced similar pressure in 2025.

Margin and restructuring inflection. The June 2024 Biogenix announcement explicitly framed the Memphis product review and exit from merchant commodity fatty acids as a move to improve operational efficiency and focus on higher-value amides and esters [S12]. The subsequent full closure of Memphis in April 2026 [S16] implies one-time restructuring charges (severance for 172 employees, decommissioning, potential environmental remediation) in FY2025–FY2026, offset over time by fixed-cost removal and mix improvement.

Pricing as a 2026 lever. The 10–25% global price increase across all Organometallix product lines effective May 2026 [S19] signals both cost inflation (tin, freight, logistics) and confidence in pricing power. Its realization will be a key determinant of FY2026 margins.

Capital intensity. Disclosed capex programs over the period include: the Axis, AL and Carrollton, KY organotin expansions (2020–early 2022) [S10]; the Gyeongju, South Korea Armoslip® expansion (construction from late 2024, +50% capacity, supply by mid-2026) [S12]; and an R&D investment of EUR 2M at PMC Isochem (undated trade headline) [S35]. Amounts for the US and Korean projects were not disclosed.

Financing. PMC's acquisitions have historically been financed privately, with terms undisclosed; the 2008 Chemtura deal was explicitly "subject to financing" [S5], indicating use of acquisition debt. Lender identities, facility sizes and covenants are not publicly disclosed.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Holding Arm Details

Holding armDescriptionUnits / subsidiaries (disclosed)

PMC Group N.A., Inc.

North American specialty chemicals holding company; President Debtosh Chakrabarti

PMC Organometallix, Inc.; PMC Biogenix, Inc.; PMC Crystal; PMC Polymer Products

PMC Group International, Inc.

Described as an "independent arm" of PMC Group; President Dr. Raj Chakrabarti

PMC Group France (→ PMC Ouvrie; PMC Isochem SAS; India rubber chemicals acquired via PMC France); PMC YM-Pharma Private Ltd. (India); Cobra Investments Management Inc. → Copperhead Chemical Company Inc., Copperhead Investments Inc.

Real estate & technology

Group service entities

PMC Real Estate, LLC (HQ building); PMC Advanced Technology, LLC (launched 2010)

Business Units

Business unitCompany's tagline (paraphrased)Core chemistryPrimary site(s)

PMC Crystal

Innovation as cornerstone

Defoamers, wax emulsions, metallic stearates, processing aids, cable filling compounds

Lansdale, PA

PMC Biogenix

Global producer of renewable-based chemicals

Fatty amides/bisamides, glycerol esters, metallic stearates, specialty esters

Gyeongju, South Korea (Memphis closed Apr 2026)

PMC Polymer Products

Innovation-driven

Additive masterbatches, flame-retardant compounds

Stockertown, PA

PMC Organometallix

Specialized stabilizers

Organotin PVC stabilizers, FASCAT® catalysts, tin intermediates, reagents

Carrollton, KY; Netherlands

PMC Rubber Chemicals

Developer/producer of rubber chemicals

Accelerators, antioxidants, antiozonants

India

PMC Pharmaceuticals India Private Limited

Custom pharmaceutical manufacturing

APIs and intermediates

India (believed to be the ex-YM-Pharma Hyderabad operation; renaming not independently confirmed)

PMC Isochem

Custom pharmaceutical manufacturing

APIs, intermediates, excipients; phosgene, hydrogenation and distillation chemistry

Vert-le-Petit, Gennevilliers, Pithiviers (France)

PMC Ouvrie

Specialty esters

Specialty esters, defoamers, surfactants, protective colloids

Lesquin, France

Copperhead Chemical

Energetic materials

Pharmaceutical-grade nitroglycerin; nitrate-ester energetics for defense

Tamaqua, PA

Analytical Segment Details

Analytical segmentUnits

A. Polymer & Performance Additives

Organometallix, Biogenix, Polymer Products, Crystal, Rubber Chemicals

B. Specialty Esters & Food/Industrial Process Aids

Ouvrie, Crystal (food defoamers)

C. Pharma & Energetics (PMC Group International)

Isochem, PMC Pharmaceuticals India / YM-Pharma, Copperhead

Segment revenue (USD Mn)

FY2023

Segment operating income (USD Mn)

FY2023

Segment operating margin (%)

FY2023

Financial Analysis

MetricFY2021FY2022FY2023FY2024FY2025

Margin

FY2021

FY2022

FY2023

FY2024

FY2025

Data Point Details

Data pointValuePeriodReliability

PMC Isochem headcount

~250 employees across 3 French sites

April 2025

Company job posting – reliable

PMC Isochem headcount at acquisition

230+ employees

Dec 2017

Press release – reliable

Chemtura oleochemicals headcount at acquisition

~275 employees

Feb 2008

Company spokesperson – reliable

PMC Biogenix Memphis headcount at closure

172 (122 union-represented)

Feb–Mar 2026

WARN notice – reliable

PMC Isochem financials (French INPI filings via aggregator)

Aggregator shows personnel costs of roughly EUR 17–18M per year (2021–2024) alongside an internally inconsistent revenue figure (~EUR 11.0M for 2021) and gross-margin series

2021–2024

Unreliable/conflicting – figures do not reconcile (a ~250-person API manufacturer with EUR 17–18M personnel cost is inconsistent with EUR 11M revenue); not used for analysis. Primary filings at Infogreffe/INPI should be consulted

Region revenue (USD Mn)

Region revenue (USD Mn)FY2023FY2024FY2025

Region revenue growth (%)

FY2023

FY2024

FY2025

Business Units by Unit

UnitUSAFranceNetherlandsIndiaSouth Korea

Organometallix

Carrollton, KY (production)

—

Production/commercial presence

——

Biogenix

Memphis, TN (closed Apr 2026)

———

Gyeongju (production; expanding)

Crystal

Lansdale, PA

————

Polymer Products

Stockertown, PA

————

Copperhead

Tamaqua, PA

————

Ouvrie

—

Lesquin

———

Isochem

—

Vert-le-Petit, Gennevilliers, Pithiviers

———

Rubber Chemicals

———

Production

—

PMC Pharmaceuticals India / YM-Pharma

———

Hyderabad

—

Share price performance (%)

Share price performance (%)FY2023

Item

Status

1/3/5-year share price performance

Not applicable (private)

Moody's / S&P / Fitch ratings

None identified

Peer valuation context

Listed peers (SONGWON, NOCIL, Croda) provide reference points for any private valuation; SONGWON's FY2025 net profit of only KRW 2,296M (preliminary) on ~KRW 1.04 trillion sales illustrates thin profitability in tin and stabilizer chemistry in 2025 [S28][S36]

Analyst Conclusions

Management guidance and consensus

Management guidance: not publicly disclosed. Consensus expectations: none (no analyst coverage). Directional signals from management actions in 2024–2026 are (i) capacity growth in Korean fatty amides, (ii) footprint rationalization in the US oleochemicals business, and (iii) aggressive price recovery in organotins.

Bull case (grounded in evidence)

  1. Pricing plus niche concentration lifts margins. A 10–25% across-the-board organotin price increase effective May 2026 [S19], in a market where PMC holds a large global share [S11], could materially expand FY2026–FY2027 margins if retained.

  2. Restructuring dividend. Exiting commodity fatty acids and closing Memphis [S12][S16], while adding 50% amide capacity in Korea [S12], should structurally improve Biogenix mix and fixed-cost absorption from 2H 2026.

  3. Strategic pharma/defense assets gain value. Copperhead's sole-US nitroglycerin status [S8] and defense-supplier recognition [S33] align with onshoring and munitions-demand trends, potentially making it the group's most valuable asset per dollar of revenue.

Bear case (grounded in evidence)

  1. Structural decline in tin chemistry. Peer data show 2025 weakness in tin intermediates with falling prices and intensified competition [S28]; price increases may accelerate substitution or share loss.

  2. Hazard and EHS tail risk. Phosgene and nitration chemistries plus a history of a 2014 EPA penalty and a 2022 plant incident [S17][S24] create low-probability, high-severity exposure.

  3. Opacity and concentration. With no published financials, unknown leverage and founder-centric governance [S14], counterparties cannot assess solvency; succession uncertainty could disrupt a portfolio that depends on owner-led deal-making.

Key catalysts and monitorables (next 12 months)

MonitorableWhy it mattersIndicator
Gyeongju ramp confirmationValidates Biogenix pivotCompany announcement or customer supply notices
Price-increase realization (Organometallix)Margin driverFollow-on announcements; distributor price lists
Memphis site disposition/remediationLiability and asset-sale potentialLocal filings, property transactions
Copperhead defense contracts/capacityGrowth in energeticsPrime-contractor supplier news; DoD industrial-base announcements
Copperhead FDA listing renewalsPharma continuityNDC/DMF listings beyond 2026 [S27]
Further carve-out acquisitions or divestituresPortfolio directionBusiness Wire releases
Leadership/succession announcementsGovernance riskPress releases
Organotin regulatory developments (EU/US)Demand riskREACH/TSCA actions

Concluding analyst verdict

PMC Group, Inc. is a durable but opaque founder-owned consolidator of niche specialty chemicals that has, over three decades, turned non-core castoffs from global majors into a nine-unit portfolio spanning organotin additives, bio-based amides, process aids, rubber chemicals, pharmaceutical CDMO capacity and defense energetics. Its most defensible assets are clear: a large global share of organotin PVC stabilizers built through the 2012–2013 Arkema and Dow transactions, heritage additive brands such as FASCAT®, Armoslip® and Kemamide®, the hazardous-chemistry and cGMP capabilities of PMC Isochem, and Copperhead's position as the sole US manufacturer of FDA-approved nitroglycerin with recognized standing in the defense supply chain.

The 2024–2026 period marks a clear pivot from expansion to rationalization. Management exited commodity fatty acids, closed the 172-person Memphis plant, shifted amide growth to South Korea, and imposed a 10–25% global price increase on organotins amid raw-material, freight and geopolitical cost pressure. These are rational responses to a soft 2025 market – one in which listed peer SONGWON saw tin-intermediate prices decline and group sales fall nearly 3% – but they also reveal that parts of the portfolio were sub-economic.

The central analytical limitation is transparency. With no disclosed revenue, profitability, leverage or governance structure, any external party – lender, customer, acquirer or supplier – must underwrite PMC on asset quality and track record rather than financial evidence. Key-person risk around the founder is material.

Verdict: PMC is best viewed as a collection of strategically valuable niche assets held within a low-disclosure family structure. For counterparties, the group is commercially credible but requires direct financial due diligence. For potential acquirers, Copperhead and the organotin franchise are the crown jewels; for competitors, PMC's 2026 pricing move is a signal of supply discipline in organotins worth monitoring closely.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitle (latest disclosed)Tenure / prior roles disclosed

Dr. Paritosh M. Chakrabarti

Founder and owner; Chairman/CEO (CEO title cited in third-party profile)

Founded PMC in 1994; author and philanthropist; founder of the Chakrabarti Foundation (1995)

Debtosh Chakrabarti

President, PMC Group N.A., Inc.

Quoted as President on the Lanxess deal (2019), Organometallix expansion (2020) and Biogenix expansion (2024); quoted as President on Dow acquisition (2013)

Dr. Raj Chakrabarti

President, PMC Group International, Inc.

VP & Chief Strategy Officer (Nov 2017) → Executive Vice President (Dec 2017) → President (by Feb 2021); led pharma acquisitions

Patti Griggs

Director of Customer & Administrative Services; Assistant to the Chairman of the Board (2008); media contact for PMC Group International

Long-tenured (since at least 2008)

Governance Overview

ItemStatus

Board composition

Not publicly disclosed (a board of directors with a chairman existed as of 2008 [S5])

Chair/CEO separation

Not publicly disclosed; founder appears to hold both ownership control and top executive role

Code of conduct

Published on website [S1]

Commercial terms & conditions

Published on website [S1]

Major Shareholders

HolderStake

Dr. Paritosh M. Chakrabarti

Owner (stake not quantified; described as owner of PMC Group)

Institutional holders (top 10)

Not applicable – no public float

Insider ownership

Effectively 100% insider/family-controlled (assessed)

Competitive Landscape

Competitors by Segment

SegmentCompetitorHQOwnershipRelevant revenue (verified)Relative positioning vs PMC

Organotin stabilizers / tin intermediates

SONGWON Industrial

South Korea

Listed (KRX)

FY2025 sales KRW 1,039,162M; Performance Chemicals division KRW 286,237M [S28]

Broader polymer-stabilizer portfolio; also active in tin intermediates; larger and more diversified than PMC's tin business

Organotin & mixed-metal PVC stabilizers

Baerlocher

Germany

Private

—

Global leader in PVC stabilizers across chemistries

Organotin & PVC additives

Galata Chemicals

USA

Private

—

Direct US organotin competitor

PVC stabilizers

Reagens

Italy

Private

—

Strong in Ca/Zn and other stabilizers

Organotin catalysts & tin chemicals

TIB Chemicals

Germany

Private

—

Direct competitor in tin catalysts

Fatty amides / slip additives

Croda (Crodamide)

UK

Listed (LSE)

—

Larger, higher-margin specialty peer

Fatty amides / oleochemical additives

Fine Organic Industries

India

Listed (NSE/BSE)

—

Low-cost Indian competitor in plastic additives

Metallic stearates

Baerlocher; Faci; Peter Greven

Germany/Italy

Private

—

Scale players in stearates

Defoamers / wax emulsions

BYK (Altana), Evonik, Michelman, Münzing, Elementis

Various

Mixed

—

Much larger additive formulators

Rubber chemicals (India)

NOCIL

India

Listed (NSE/BSE)

FY2025 (Mar-25) revenue from operations INR 1,393 crore, down from INR 1,445 crore [S29]

India's largest rubber-chemicals maker; PMC's India unit is a much smaller niche player (assessed)

Rubber chemicals (global)

Lanxess, Sunsine, Kumho Petrochemical

Various

Listed

—

Scale and cost leaders

Pharma CDMO (small-molecule, hazardous chemistry)

Seqens, Axplora (ex-Novasep), Siegfried, Olon, Minakem

Europe

Mixed

—

Larger European CDMOs; PMC Isochem competes in phosgenation and niche APIs

Generic APIs (India)

Numerous Indian API makers

India

Mixed

—

Highly competitive; fluoroquinolones commoditized

Defense energetics (nitrate esters)

Government-owned/contractor-operated US ammunition plants and other primes' captive capacity

USA

Government/contractor

—

Copperhead is a specialized private-sector supplier

Peer Comparison FY2025

MetricSONGWON (FY2025)NOCIL (FY Mar-2025)

Revenue

KRW 1,039,162M [S28]

INR 1,393 crore [S29]

Revenue growth YoY

-2.9% [S28]

≈-4% [S29]

Gross margin

13.7% [S28]

—

Recent Developments

Dates are as reported.

Within the 18-month window

DateEventSignificanceSource
9 Apr 2025PMC Isochem posts production operator vacancies (5-shift pattern) at Pithiviers, describing itself as ~250 staff on 3 sites with 50 years' experience in custom manufacturing of intermediates, excipients and APIsIndicates ongoing French operations and hiring[S23]
Aug 2025New corporate website assets published (logo, design)Start of rebrand[S1]
Nov 2025Website icon/brand assets updatedRebrand continues[S1]
Feb 2026New business-unit logos posted for all nine unitsBrand architecture refresh[S1]
Feb 2026PMC Biogenix files WARN notice with Tennessee Dept. of Labor for permanent closure of Memphis plantMajor footprint reduction; 172 jobs[S16][S17]
3 Mar 2026Daily Memphian reports closure of the facility on 26 April with 172 layoffsPublic disclosure of closure[S16]
4 Mar 2026Hoodline reports 122 of 172 workers are union-represented; Greater Memphis rapid-response team engaged; references 2022 safety incidentLabor and community impact[S17]
24 Apr 2026PMC Organometallix announces global price increase of 10–25% across all product lines effective 1 May 2026, citing raw materials, freight/logistics and the Iran-conflict geopolitical environmentPricing power; cost inflation signal[S19]
26 Apr 2026Scheduled permanent closure of Memphis Pope Street plantCompletion of Biogenix US exit from Memphis[S16][S18]
Mid-2026Targeted start of new Armoslip® supply from Gyeongju (+50% capacity)Capacity ramp; completion not independently confirmed[S12]
Jul–Aug 2026FDA NDC listings for Copperhead diluted nitroglycerin bulk ingredient active (data synced Jul/Aug 2026)Confirms continuing pharma bulk supply[S26]
Through 2026Copperhead DMF/NDC bulk listings: two powder listings ended 31 Dec 2025; another runs to 31 Dec 2026Routine regulatory listing lifecycle; monitor renewals[S27]
Aug 2026New Copperhead logo added to PMC websiteCopperhead brand integration[S1]

Context events (preceding window, last ~3 years)

DateEventSignificanceSource
14 Mar 2023Copperhead receives Northrop Grumman 2022 Strategic Excellence AwardDefense supply-chain validation[S33]
14 Mar 2023PMC Group and Chakrabarti Foundation donate land/property to Ramakrishna Mission Belur MathFounder philanthropy; ownership confirmed[S14]
21 Jun 2024PMC Biogenix announces Gyeongju expansion and Memphis restructuringStrategic pivot in oleochemicals[S12]
2,022Memphis plant safety incident with fire response and air monitoringEHS history[S17]

Company Snapshot

1994

Founded

NJ, US

Headquarters

SWOT Analysis

Strengths

  • Leading global position in organotin PVC stabilizers: Arkema (2012) + Dow (2013) deals gave PMC a large share of the world tin PVC stabilizer market [S11]
  • Unique US pharma asset: Copperhead: sole US manufacturer of FDA-approved nitroglycerin for 70+ years; active FDA bulk listings in 2026 [S8][S26]
  • Defense supply-chain credentials: Northrop Grumman 2022 Strategic Excellence Award to Copperhead [S33]
  • Proven carve-out integration capability: 20 acquisitions on company timeline since 1994, mostly from majors [S2]
  • High-barrier hazardous chemistry: Phosgene chemistry at Vert-le-Petit; nitration at Tamaqua; FDA-audited cGMP plants [S6][S22][S31]
  • Pricing power in concentrated niches: 10–25% global price increase across Organometallix lines (May 2026) [S19]
  • Large owned land bank / sites: 875-acre Tamaqua site; 400-acre Carrollton site; owned HQ [S8][S25][S2]

Weaknesses

  • No financial transparency: No public financial statements; dossier unable to verify any group financial metric
  • Legacy commodity exposure required costly exit: Memphis closure; 172 jobs lost [S16]
  • EHS history: 2014 EPA Clean Air Act penalty (Organometallix) [S24]; 2022 Memphis incident [S17]
  • Key-person and succession concentration: Founder-owned; leadership roles held by Chakrabarti family-surnamed executives [S8][S12][S14]
  • Fragmented, heterogeneous portfolio: Nine BUs spanning PVC additives, food defoamers, rubber chemicals, APIs and defense energetics [S1]
  • Disclosure inconsistencies: Website dates Lanxess deal December 2020 vs press release closing 30 Dec 2019 [S2][S3]; website contains placeholder "Lorem ipsum" text [S1]

Opportunities

  • Fatty-amide demand growth served from expanded Korean capacity: +50% Armoslip® capacity, supply from mid-2026 [S12]
  • Defense munitions/propellant demand upcycle: Copperhead's energetics role and supplier recognition [S8][S33]
  • Pharma supply-chain onshoring (US/EU): Copperhead US nitroglycerin; Isochem French cGMP sites [S6][S8]
  • Drug-delivery platform monetization: ISODEL® NCA/PAA one-stop shop [S35]
  • Geographic distribution expansion: Safic-Alcan Africa (2021); ChemPoint North America [S15][S25]
  • Further carve-outs from majors: Ongoing portfolio pruning by large chemical companies; PMC's repeated buyer track record [S2]

Threats

  • Weak PVC and tin-intermediate markets; Asian price competition: Songwon reports declining tin-intermediate prices and intensified competition in 2025 [S28]
  • Raw-material, freight and geopolitical cost shocks: PMC cites raw materials, freight and the Iran conflict for 2026 price increase [S19]
  • Regulatory restrictions on organotins: EU REACH organotin restrictions (sector-wide); substitution toward non-tin systems
  • Import/dumping pressure in Indian rubber chemicals: NOCIL cites dumping pressure in domestic market [S29]
  • Labor and community relations after closures: 122 union-represented workers affected in Memphis [S17]
  • Price-increase customer pushback / share loss: 10–25% increases risk customer switching in a market with Asian alternatives [S19][S28]

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
9 Apr 2025PMC Isochem posts production operator vacancies (5-shift pattern) at Pithiviers, describing itself as ~250 staff on 3 sites with 50 years' experience in custom manufacturing of intermediates, excipients and APIs [S23]Indicates ongoing French operations and hiring
Aug 2025New corporate website assets published (logo, design) [S1]Start of rebrand
Nov 2025Website icon/brand assets updated [S1]Rebrand continues
Feb 2026New business-unit logos posted for all nine units [S1]Brand architecture refresh
Feb 2026PMC Biogenix files WARN notice with Tennessee Dept. of Labor for permanent closure of Memphis plant [S16][S17]Major footprint reduction; 172 jobs
3 Mar 2026Daily Memphian reports closure of the facility on 26 April with 172 layoffs [S16]Public disclosure of closure
4 Mar 2026Hoodline reports 122 of 172 workers are union-represented; Greater Memphis rapid-response team engaged; references 2022 safety incident [S17]Labor and community impact
24 Apr 2026PMC Organometallix announces global price increase of 10–25% across all product lines effective 1 May 2026, citing raw materials, freight/logistics and the Iran-conflict geopolitical environment [S19]Pricing power; cost inflation signal
26 Apr 2026Scheduled permanent closure of Memphis Pope Street plant [S16][S18]Completion of Biogenix US exit from Memphis
Mid-2026Targeted start of new Armoslip® supply from Gyeongju (+50% capacity) [S12]Capacity ramp; completion not independently confirmed
Jul–Aug 2026FDA NDC listings for Copperhead diluted nitroglycerin bulk ingredient active (data synced Jul/Aug 2026) [S26]Confirms continuing pharma bulk supply
Through 2026Copperhead DMF/NDC bulk listings: two powder listings ended 31 Dec 2025; another runs to 31 Dec 2026 [S27]Routine regulatory listing lifecycle; monitor renewals
Aug 2026New Copperhead logo added to PMC website [S1]Copperhead brand integration
14 Mar 2023Copperhead receives Northrop Grumman 2022 Strategic Excellence Award [S33]Defense supply-chain validation
14 Mar 2023PMC Group and Chakrabarti Foundation donate land/property to Ramakrishna Mission Belur Math [S14]Founder philanthropy; ownership confirmed
21 Jun 2024PMC Biogenix announces Gyeongju expansion and Memphis restructuring [S12]Strategic pivot in oleochemicals
2022Memphis plant safety incident with fire response and air monitoring [S17]EHS history

Sources

Sources

  1. S1PMC Group corporate website, home page (pmc-group.com) – business units, locations, HQ, latest news — Accessed Oct 2026
  2. S2PMC Group website, "PMC History" ( — Accessed Oct 2026 (pmc-group.com)
  3. S3Business Wire / BioSpace: "PMC Group Completes Acquisition of Lanxess' Organotin Specialties Business Assets" — 2 Jan 2020
  4. S4Business Wire (via ANSA / Business Wire China): "PMC Group Announces Agreement to Acquire Lanxess' Organotin Specialties Business" — 13 Nov 2019
  5. S5Lube Report (lubesngreases.com): "Chemtura Sheds Oleochemicals" — 2008
  6. S6Business Wire: "PMC Group International Announces Acquisition of Pharma Company in France" — 4 Dec 2017
  7. S7Business Wire (via Business Wire China / Korea Newswire): "PMC Group International Announces Acquisition of Pharma Company in India" — 2 Nov 2017
  8. S8Business Wire: "PMC Group International Announces Acquisition of Copperhead Chemical Company" — 22–23 Feb 2021
  9. S9Speciality Chemicals Magazine (specchemonline.com): "Isochem owner buys Copperhead" — 30 Mar 2021
  10. S10Business Wire / BioSpace: "PMC Organometallix Continues Expansion" — 9–10 Dec 2020
  11. S11International Tin Association (internationaltin.org): PMC completes Dow and Arkema tin acquisitions — Jan 2013
  12. S12Business Wire: "PMC Biogenix Announces Expansion and Restructure" — 21 Jun 2024
  13. S13Business Wire: "PMC Biogenix Announces Price Increase on Certain Product Lines" — 13 Nov 2020
  14. S14Business Wire: "PMC Group and The Chakrabarti Foundation Make Donation to Ramakrishna Mission Saradapitha Belur Math of West Bengal" — 14 Mar 2023
  15. S15Business Wire: "Safic-Alcan Extends Its Distribution Agreement With PMC Organometallix to the African Continent" — 25 Jun 2021
  16. S16The Daily Memphian: "Chemical manufacturer closing Memphis facility, laying off 172" — 3 Mar 2026
  17. S17Hoodline: "North Memphis Chemical Plant Shutting Down, 172 Jobs On The Line" — 4 Mar 2026
  18. S18WhatNow Memphis: "Longtime Memphis Chemical Plant to Shut Down, 170+ Workers to Be Laid Off" — 2026
  19. S19Business Wire (via Offshore Source): "PMC Organometallix Announces Price Increase on All Products" — 24 Apr 2026
  20. S20SpecialChem supplier page: PMC Group (coatings) — Accessed Oct 2026
  21. S21GlobalData (ResearchPool): "PMC Group, Inc. – Company Review" (summary) — Accessed Oct 2026
  22. S22Wikipedia: "Isochem" — Accessed Oct 2026
  23. S23France Travail job posting, PMC Isochem, Pithiviers (Offer 4948298) — 9 Apr 2025
  24. S24US EPA Administrative Dockets: CAA-04-2014-1506(b), PMC Organometallix, Inc. — 2014
  25. S25ChemPoint: PMC Organometallix supplier pages — Accessed Oct 2026
  26. S26HelloPharmacist NDC lookup (openFDA/DailyMed data): Copperhead diluted nitroglycerin listings — Data synced Jul–Aug 2026
  27. S27PharmaCompass: Copperhead Chemical Company NDC/DMF listings — Accessed Oct 2026
  28. S28SONGWON Industrial Group: FY2025 financial results release — 4 Mar 2026
  29. S29Quartr: NOCIL Q4 FY24/25 earnings summary — May 2025
  30. S30CHEManager: "PMC Buys Isochem's Pharma Business" — Dec 2017
  31. S31GlobalData (ResearchPool): "Copperhead Chemical Company – Company Review" (summary) — Accessed Oct 2026
  32. S32GoWork.fr: PMC Isochem profile (aggregated INPI data – flagged unreliable/conflicting) — Accessed Oct 2026
  33. S33Business Wire: "PMC Group International Announces Copperhead Chemical Company Inc. Earns Northrop Grumman Strategic Excellence Award" — 14 Mar 2023
  34. S35PharmaCompass news aggregation: PMC Isochem headlines (ISODEL® drug delivery; EUR 2M R&D investment) — Undated headlines
  35. S36SONGWON Industrial Group: preliminary FY2025 results — 30 Jan 2026

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.